JP2017531448A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017531448A5 JP2017531448A5 JP2017537016A JP2017537016A JP2017531448A5 JP 2017531448 A5 JP2017531448 A5 JP 2017531448A5 JP 2017537016 A JP2017537016 A JP 2017537016A JP 2017537016 A JP2017537016 A JP 2017537016A JP 2017531448 A5 JP2017531448 A5 JP 2017531448A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- cells
- motif
- ligand
- fibronectin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 34
- 239000003446 ligand Substances 0.000 claims description 21
- 108010067306 Fibronectins Proteins 0.000 claims description 17
- 102000016359 Fibronectins Human genes 0.000 claims description 17
- 239000012634 fragment Substances 0.000 claims description 17
- 210000004027 cell Anatomy 0.000 claims description 12
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 10
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 10
- 210000000173 T-lymphoid precursor cell Anatomy 0.000 claims description 10
- NNRFRJQMBSBXGO-CIUDSAMLSA-N (3s)-3-[[2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-oxobutanoic acid Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O NNRFRJQMBSBXGO-CIUDSAMLSA-N 0.000 claims description 8
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 8
- 229960002897 heparin Drugs 0.000 claims description 8
- 229920000669 heparin Polymers 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 238000004113 cell culture Methods 0.000 claims description 7
- 239000001963 growth medium Substances 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 claims description 6
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 claims description 6
- 102000000704 Interleukin-7 Human genes 0.000 claims description 6
- 108010002586 Interleukin-7 Proteins 0.000 claims description 6
- 102000036693 Thrombopoietin Human genes 0.000 claims description 6
- 108010041111 Thrombopoietin Proteins 0.000 claims description 6
- 229940100994 interleukin-7 Drugs 0.000 claims description 6
- 239000002609 medium Substances 0.000 claims description 5
- 210000000130 stem cell Anatomy 0.000 claims description 5
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 239000003102 growth factor Substances 0.000 claims description 4
- 101000829980 Homo sapiens Ral guanine nucleotide dissociation stimulator Proteins 0.000 claims description 3
- 102100023320 Ral guanine nucleotide dissociation stimulator Human genes 0.000 claims description 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- -1 SCF Proteins 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000004806 packaging method and process Methods 0.000 claims description 2
- 108010056030 retronectin Proteins 0.000 claims description 2
- 239000013603 viral vector Substances 0.000 claims description 2
- 239000011324 bead Substances 0.000 claims 3
- 208000024908 graft versus host disease Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 238000010322 bone marrow transplantation Methods 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 230000003750 conditioning effect Effects 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 238000001890 transfection Methods 0.000 claims 1
- 102000005650 Notch Receptors Human genes 0.000 description 9
- 108010070047 Notch Receptors Proteins 0.000 description 9
- 239000011325 microbead Substances 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1459539A FR3026744B1 (fr) | 2014-10-06 | 2014-10-06 | Methode de generation de progeniteurs de cellules t |
| FR1459539 | 2014-10-06 | ||
| PCT/EP2015/072889 WO2016055396A1 (fr) | 2014-10-06 | 2015-10-05 | Méthode de génération de progéniteurs de cellules t |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020209370A Division JP2021072779A (ja) | 2014-10-06 | 2020-12-17 | T細胞前駆細胞を生成するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017531448A JP2017531448A (ja) | 2017-10-26 |
| JP2017531448A5 true JP2017531448A5 (enExample) | 2018-11-15 |
| JP6898240B2 JP6898240B2 (ja) | 2021-07-07 |
Family
ID=52102849
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017537016A Active JP6898240B2 (ja) | 2014-10-06 | 2015-10-05 | T細胞前駆細胞を生成するための方法 |
| JP2020209370A Pending JP2021072779A (ja) | 2014-10-06 | 2020-12-17 | T細胞前駆細胞を生成するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020209370A Pending JP2021072779A (ja) | 2014-10-06 | 2020-12-17 | T細胞前駆細胞を生成するための方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12071635B2 (enExample) |
| EP (2) | EP3204492B1 (enExample) |
| JP (2) | JP6898240B2 (enExample) |
| CA (1) | CA2963756C (enExample) |
| DK (1) | DK3204492T3 (enExample) |
| ES (1) | ES2914082T3 (enExample) |
| FR (1) | FR3026744B1 (enExample) |
| HU (1) | HUE059468T2 (enExample) |
| PL (1) | PL3204492T3 (enExample) |
| PT (1) | PT3204492T (enExample) |
| WO (1) | WO2016055396A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3440198A4 (en) | 2016-04-08 | 2019-11-06 | The Governing Council of the Universtiy of Toronto | PROCESS FOR THE PRODUCTION OF PRE-TREATMENT T CELLS FROM TRUNK AND / OR PRECURSOR CELLS AND USE THEREOF |
| IL268641B2 (en) * | 2017-02-13 | 2024-10-01 | Assist Publique Hopitaux Paris Aphp | Method for generating t cells progenitors |
| CN112041431A (zh) * | 2018-02-14 | 2020-12-04 | 桑尼布鲁克研究所 | 产生t细胞谱系细胞的方法 |
| FR3079239A1 (fr) * | 2018-03-23 | 2019-09-27 | Centre National De La Recherche Scientifique | Nouvelle methode d’obtention de cellules t a partir de cellules souches pluripotentes, et leurs utilisations |
| EP3774867A1 (en) * | 2018-04-10 | 2021-02-17 | Stichting Sanquin Bloedvoorziening | Chimeric notch receptors |
| JP2023553313A (ja) | 2020-11-30 | 2023-12-21 | チョ ファーマ インコーポレイテッド | 細胞を富化するための抗体 |
| EP4426319A1 (en) | 2021-11-04 | 2024-09-11 | APHP (Assistance Publique - Hôpitaux de Paris) | Method for generating nk cells |
| WO2024175738A1 (en) | 2023-02-22 | 2024-08-29 | Smart Immune | Method for thymus regeneration |
| WO2025012449A1 (en) | 2023-07-12 | 2025-01-16 | Smart Immune | Biobank of cellular banks having specific homozygous hla haplotypes and uses thereof for treating patients |
| WO2025219552A1 (en) | 2024-04-17 | 2025-10-23 | Assitance Publique Hopitaux De Paris | Method for producing t cell progenitors from human pluripotent stem cells |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6093531A (en) | 1997-09-29 | 2000-07-25 | Neurospheres Holdings Ltd. | Generation of hematopoietic cells from multipotent neural stem cells |
| JP2001525176A (ja) | 1997-12-04 | 2001-12-11 | デューク・ユニバーシティー | Cd7+cd34−lin−造血細胞を単離し、使用する方法 |
| EA012520B1 (ru) * | 2003-08-22 | 2009-10-30 | Такара Био Инк. | Способ получения цитотоксических лимфоцитов |
| US10059923B2 (en) | 2008-01-30 | 2018-08-28 | Memorial Sloan Kettering Cancer Center | Methods for off-the-shelf tumor immunotherapy using allogeneic T-cell precursors |
| RU2535966C2 (ru) | 2008-09-12 | 2014-12-20 | Криопрашис Криобиоложия Лтда. | Клеточная терапия ишемической ткани |
| US8772028B2 (en) | 2008-11-07 | 2014-07-08 | Sunnybrook Health Sciences Centre | CD34+CD7+CD5+CD1a-human progenitor T-cells produced in vitro and methods of using |
| WO2011068962A1 (en) * | 2009-12-03 | 2011-06-09 | The University Of Utah Research Foundation | Methods for generating t lymphocytes from hematopoietic stem cells |
| US20130095079A1 (en) | 2010-04-09 | 2013-04-18 | Fred Hutchinson Cancer Research Center | Compositions and methods for providing hematopoietic function without hla matching |
| WO2013074916A1 (en) | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla |
| US9834755B2 (en) | 2011-12-08 | 2017-12-05 | Fred Hutchinson Cancer Research Center | Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells |
| WO2014110353A1 (en) * | 2013-01-11 | 2014-07-17 | The Trustees Of The University Of Pennsylvania | Notch ligand bound bicompatible substrates and their use in bone formation |
| EP3027755B1 (en) | 2013-08-02 | 2019-10-09 | The Regents of The University of California | Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors |
| US20170128556A1 (en) | 2013-12-26 | 2017-05-11 | Thyas Co. Ltd. | Immunotherapy using t precursor cells derived from pluripotent stem cells having rearranged t cell receptor genes |
| KR20160145802A (ko) | 2014-04-23 | 2016-12-20 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 요법에 사용하기 위한 키메라 항원 수용체 (car) 및 이의 제조 방법 |
| US10131876B2 (en) | 2014-04-24 | 2018-11-20 | Miltenyi Biotec Gmbh | Method for automated generation of genetically modified T cells |
| WO2016039933A1 (en) * | 2014-09-11 | 2016-03-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Lentiviral vector for treating hemoglobin disorders |
-
2014
- 2014-10-06 FR FR1459539A patent/FR3026744B1/fr active Active
-
2015
- 2015-10-05 ES ES15771979T patent/ES2914082T3/es active Active
- 2015-10-05 EP EP15771979.0A patent/EP3204492B1/fr active Active
- 2015-10-05 WO PCT/EP2015/072889 patent/WO2016055396A1/fr not_active Ceased
- 2015-10-05 US US15/516,731 patent/US12071635B2/en active Active
- 2015-10-05 JP JP2017537016A patent/JP6898240B2/ja active Active
- 2015-10-05 PL PL15771979.0T patent/PL3204492T3/pl unknown
- 2015-10-05 PT PT157719790T patent/PT3204492T/pt unknown
- 2015-10-05 EP EP22152734.4A patent/EP4036224A1/fr not_active Withdrawn
- 2015-10-05 DK DK15771979.0T patent/DK3204492T3/da active
- 2015-10-05 HU HUE15771979A patent/HUE059468T2/hu unknown
- 2015-10-05 CA CA2963756A patent/CA2963756C/fr active Active
-
2020
- 2020-12-17 JP JP2020209370A patent/JP2021072779A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017531448A5 (enExample) | ||
| CN107922925B (zh) | 用于自然杀伤细胞扩增的方法 | |
| CA2954534C (en) | Manufacture and cryopreservation of fucosylated cells for therapeutic use | |
| ES2931530T3 (es) | Método para generar progenitores de células T | |
| JP6898240B2 (ja) | T細胞前駆細胞を生成するための方法 | |
| JP6775426B2 (ja) | 臍帯血由来のプールnk細胞並びにがん及び慢性感染症の治療のためのこれらの用途 | |
| Netsrithong et al. | Engineered T cells from induced pluripotent stem cells: from research towards clinical implementation | |
| Brauer et al. | T cell genesis: in vitro veritas est? | |
| Alidadi et al. | Combining the induced pluripotent stem cell (iPSC) technology with chimeric antigen receptor (CAR)-based immunotherapy: recent advances, challenges, and future prospects | |
| IL277467B2 (en) | Method for producing natural killer cells | |
| Netsrithong et al. | Advances in adoptive cell therapy using induced pluripotent stem cell-derived T cells | |
| JP2023522326A (ja) | 条件付き不死化に関する制御可能な導入遺伝子を含む人工多能性細胞 | |
| Guo et al. | Generation and clinical potential of functional T lymphocytes from gene-edited pluripotent stem cells | |
| US20200263136A1 (en) | Methods of preparing hematopoietic progenitor cells in vitro | |
| JP7743980B2 (ja) | ヒトT細胞由来iPS細胞由来の細胞傷害性T細胞 | |
| Kumar et al. | Multiplexed iPSC platform for advanced NK cell immunotherapies | |
| Better et al. | 287. Production of KTE-C19 (Anti-CD19 CAR T Cells) for ZUMA-1: a Phase 1/2 Multi-Center Study evaluating safety and efficacy in subjects with refractory aggressive Non-Hodgkin Lymphoma (NHL) | |
| JP2025533901A (ja) | グローバル、民族、又は疾患特異的集団をカバーするための同種異系細胞療法のための免疫適合性細胞 | |
| WO2008056734A1 (en) | Method for producing dendritic cells from human embryonic stem cells | |
| Chen et al. | Advances and Challenges in the Ex Vivo Production of Megakaryocytes and Platelets | |
| Lisini et al. | Stem cell production: Processes, practices, and regulation: Stem cell culture and expansion: Role of culture, types of cells, growth conditions, media nutrients, growth factors, growth phase cycle | |
| Cantore et al. | 286. Genome Editing of Inducible Cell Lines for Scalable Production of Improved Lentiviral Vectors for Human Gene Therapy | |
| Lisini et al. | Stem Cell Production: Processes, Practices, and Regulation | |
| Jain et al. | Stem Cells: Allogeneic Cells for Cellular Immunotherapy | |
| Zhu et al. | Feeder-free advances in T cell development and therapy |